Safety of Alpha-Adrenergic Receptor Antagonists in Heart Failure
نویسندگان
چکیده
منابع مشابه
Beta-adrenergic receptor antagonists and chronic heart failure in children
Chronic congestive heart failure (HF) occurs in infants and children as a result of systemic ventricle incompetence. Neurohormonal activation is thought to be the main consequence of cardiac pump failure and cause of further worsening. Several large multicenter randomized trials have demonstrated that beta-adrenergic blocking agents can improve ventricular ejection fraction, symptoms, and survi...
متن کاملVasopressin receptor antagonists in heart failure.
Vasopressin receptor antagonists are a new class of drugs that address the problems of fluid retention, hyponatremia, and renal dysfunction in heart failure. Elevated vasopressin levels in heart failure cause myocardial fibrosis, hypertrophy and vasoconstriction by activating the V1a receptors, as well as water retention and hyponatremia by activating V2 receptors. Antagonism of V1a receptors a...
متن کاملSympathetic cerebral vasoconstriction blocked by adrenergic alpha receptor antagonists.
s . 240 from the American Heart Association 265 Report of the Joint Committee for Stroke Facilities— VI I . Medical and Surgical Management of Stroke 269
متن کاملArginine Vasopressin Receptor Antagonists for Heart Failure
eart failure (HF) is among the most common causes of ospitalization, and its incidence will likely increase in an ging population of “survivors” (1). Pharmacological treatent targeted at neurohormonal activation has improved urvival, but mortality remains substantial in patients with F, thus warranting the search for novel therapeutic aproaches. Novel agents under investigation for the treatent...
متن کاملCombination therapy with beta-adrenergic receptor antagonists and phosphodiesterase inhibitors for chronic heart failure.
Abstract Rational use of phosphodiesterase inhibitors represents an ongoing controversy in contemporary pharmacotherapy for heart failure. In randomized clinical trials, phosphodiesterase inhibitors increased cardiac output at the expense of worsening the rates of sudden cardiac death and cardiovascular mortality. Preliminary findings from ongoing clinical and preclinical investigations of phos...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JACC: Heart Failure
سال: 2018
ISSN: 2213-1779
DOI: 10.1016/j.jchf.2018.06.015